About agilent technologies inc. - A
A At a Glance
Phone | 1-408-553-2424 | Revenue | 6.83B | |
Industry | Medical Specialties | Net Income | 1.24B | |
Sector | Health Technology | Employees | 18,100 | |
Fiscal Year-end | 10 / 2024 | |||
View SEC Filings |
A Valuation
P/E Current | 26.646 |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | 24.675 |
Price to Sales Ratio | 4.478 |
Price to Book Ratio | 5.166 |
Price to Cash Flow Ratio | 17.267 |
Enterprise Value to EBITDA | 16.802 |
Enterprise Value to Sales | 4.669 |
Total Debt to Enterprise Value | 0.091 |
A Efficiency
Revenue/Employee | 377,513.812 |
Income Per Employee | 68,508.287 |
Receivables Turnover | 4.912 |
Total Asset Turnover | 0.642 |
A Liquidity
Current Ratio | 2.611 |
Quick Ratio | 1.968 |
Cash Ratio | 0.992 |
A Profitability
Gross Margin | 54.427 |
Operating Margin | 23.826 |
Pretax Margin | 19.596 |
Net Margin | 18.147 |
Return on Assets | 11.646 |
Return on Equity | 22.242 |
Return on Total Capital | 14.181 |
Return on Invested Capital | 14.729 |
A Capital Structure
Total Debt to Total Equity | 49.598 |
Total Debt to Total Capital | 33.154 |
Total Debt to Total Assets | 26.935 |
Long-Term Debt to Equity | 48.811 |
Long-Term Debt to Total Capital | 32.628 |
Agilent Technologies Inc. in the News
Running low on Ozempic or another weight loss drug? A new tracker can help
Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.
Nestlé launches food line targeting Ozempic, other weight-loss drug users
Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.
25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.
Janet Yellen walks back Biden's comments US taxpayers on hook for Baltimore bridge collapse
Treasury Secretary Janet Yellen appeared to walk back comments from President Biden that American taxpayers would foot the bill for the Francis Scott Key Bridge collapse in Baltimore.
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug
Wegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Build-A-Bear and Warren Buffett's 'Squishmallows' maker square off in court
Build-A-Bear and Jazwares, the Berkshire-Hathaway-owned company that makes popular "Squishmallows," sued each other on Monday. Jazwares claims Build-A-Bear ripped off its designs.
Build-A-Bear Workshop shocks with 'After Dark' collection of adults-only stuffed animals
Build-A-Bear Workshop has left some people scratching their heads with an "After Dark" collection of 18-or-older stuffed animals for Valentine's Day.
Maersk pauses Red Sea voyages a day after Houthis attack ship
Maersk said it will pause all voyages through the Red Sea and Suez Canal until at least Jan. 2, after one of its ships was attacked by Houthi rebels on Saturday.
Shipping giant to resume Red Sea voyages with Operation Prosperity Guardian in place
Maersk, the Denmark-based shipping giant, announce plans Sunday to start sending ships through the Red Sea and Suez Canal once Operation Prosperity Guardian is in place.
Ozempic, Wegovy and other weight loss drugs present holiday challenges
Holiday prep may include forgoing doses for some people taking medications popularly used to facilitate weight loss. Those who do that need to be careful when resuming them, an expert said.